Cytek Biosciences, Inc.
CTKB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001831915
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
154
- −11 vs. Q1 2026
- Total value $361.05M
Superinvestors holding CTKB
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by CTKB insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Jun 2, 2025 | McCombe William D.Chief Financial Officer | PPurchaseCommon Stock | +35K | $2.78 | +$97.3K | 55.75K | +168.7% | SEC |
| Apr 23, 2024 | Apr 19, 2024 | Yan MingCHIEF TECHNOLOGY OFFICER | SSaleCommon Stock | −20K | $5.87 | −$117.4K | 5.99M | −0.3% | SEC10b5-1 |
| Apr 11, 2024 | Apr 9, 2024 | Yan MingCHIEF TECHNOLOGY OFFICER | SSaleCommon Stock | −1.9K | $7.0021 | −$13.3K | 6.01M | 0.0% | SEC |
| Mar 19, 2024 | Mar 18 – Mar 19, 2024 | Yan MingCHIEF TECHNOLOGY OFFICER | SSaleCommon Stock | −40K | $6.74 | −$269.6K | 6.01M | −0.7% | SEC10b5-1 |
| Dec 27, 2023 | Dec 26, 2023 | Jeanmonod PatrikChief Financial Officer | SSaleCommon Stock | −3K | $9.50 | −$28.5K | 93.4K | −3.1% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in CTKB at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,578,643 | $42.43M | 0.00% | −7,428,626−43.7% | Reduced |
| MILLENNIUM MANAGEMENT LLC | 9,338,010 | $41.37M | 0.03% | +3,046,212+48.4% | Added |
| Boston Partners | 7,660,943 | $33.94M | 0.03% | +1,858,170+32.0% | Added |
| HHLR ADVISORS, LTD.SuperinvestorHHLR Advisors (Hillhouse) | 6,657,030 | $29.49M | 3.54% | 00.0% | Unchanged |
| Topline Capital Management, LLC | 6,283,450 | $27.84M | 7.22% | −781,031−11.1% | Reduced |